CN102204904A - 左旋奥拉西坦在制备预防或治疗认知功能障碍药物中的应用 - Google Patents
左旋奥拉西坦在制备预防或治疗认知功能障碍药物中的应用 Download PDFInfo
- Publication number
- CN102204904A CN102204904A CN2010101368633A CN201010136863A CN102204904A CN 102204904 A CN102204904 A CN 102204904A CN 2010101368633 A CN2010101368633 A CN 2010101368633A CN 201010136863 A CN201010136863 A CN 201010136863A CN 102204904 A CN102204904 A CN 102204904A
- Authority
- CN
- China
- Prior art keywords
- oxiracetam
- medicine
- handed
- handed oxiracetam
- purposes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 54
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- 208000010877 cognitive disease Diseases 0.000 title claims abstract description 20
- 229940079593 drug Drugs 0.000 claims abstract description 9
- 239000000463 material Substances 0.000 claims abstract description 9
- IHLAQQPQKRMGSS-UHFFFAOYSA-N oxiracetam Chemical compound NC(=O)CN1CC(O)CC1=O IHLAQQPQKRMGSS-UHFFFAOYSA-N 0.000 claims description 146
- 229960001227 oxiracetam Drugs 0.000 claims description 137
- 230000002265 prevention Effects 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 11
- 239000007924 injection Substances 0.000 claims description 10
- 238000002347 injection Methods 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 5
- 230000000007 visual effect Effects 0.000 claims description 4
- 229940100691 oral capsule Drugs 0.000 claims description 3
- 229940096978 oral tablet Drugs 0.000 claims description 3
- 230000007074 memory dysfunction Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 12
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 abstract description 2
- 206010070863 Toxicity to various agents Diseases 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 34
- 241001465754 Metazoa Species 0.000 description 31
- 238000011534 incubation Methods 0.000 description 18
- 241000282472 Canis lupus familiaris Species 0.000 description 17
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 16
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 16
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 16
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 16
- 229960002646 scopolamine Drugs 0.000 description 16
- 238000012549 training Methods 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 210000002784 stomach Anatomy 0.000 description 11
- 230000009182 swimming Effects 0.000 description 11
- 230000037396 body weight Effects 0.000 description 10
- 238000012347 Morris Water Maze Methods 0.000 description 9
- 206010012289 Dementia Diseases 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 210000002381 plasma Anatomy 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000007492 two-way ANOVA Methods 0.000 description 8
- 239000008187 granular material Substances 0.000 description 7
- 238000011160 research Methods 0.000 description 6
- 206010008120 Cerebral ischaemia Diseases 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 230000001149 cognitive effect Effects 0.000 description 5
- 238000011049 filling Methods 0.000 description 5
- -1 hydroxypropyl Chemical group 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 201000006474 Brain Ischemia Diseases 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 206010008118 cerebral infarction Diseases 0.000 description 4
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 230000002146 bilateral effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 230000015654 memory Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 208000006888 Agnosia Diseases 0.000 description 2
- 241001047040 Agnosia Species 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 206010003062 Apraxia Diseases 0.000 description 2
- 238000001061 Dunnett's test Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 201000007201 aphasia Diseases 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 210000001168 carotid artery common Anatomy 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 230000007087 memory ability Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- QVPLPSZGHFSYEQ-UHFFFAOYSA-N 2-amino-2-hydroxybutanoic acid Chemical compound CCC(N)(O)C(O)=O QVPLPSZGHFSYEQ-UHFFFAOYSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical group CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- ZRJBHWIHUMBLCN-SEQYCRGISA-N Huperzine A Natural products N1C(=O)C=CC2=C1C[C@H]1/C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-SEQYCRGISA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 241000531807 Psophiidae Species 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- ZRJBHWIHUMBLCN-UHFFFAOYSA-N Shuangyiping Natural products N1C(=O)C=CC2=C1CC1C(=CC)C2(N)CC(C)=C1 ZRJBHWIHUMBLCN-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229960002298 aminohydroxybutyric acid Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- YQGDEPYYFWUPGO-UHFFFAOYSA-N gamma-amino-beta-hydroxybutyric acid Chemical compound [NH3+]CC(O)CC([O-])=O YQGDEPYYFWUPGO-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- ZRJBHWIHUMBLCN-YQEJDHNASA-N huperzine A Chemical compound N1C(=O)C=CC2=C1C[C@H]1\C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-YQEJDHNASA-N 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229940090044 injection Drugs 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 150000003233 pyrroles Chemical class 0.000 description 1
- ZRJBHWIHUMBLCN-BMIGLBTASA-N rac-huperzine A Natural products N1C(=O)C=CC2=C1C[C@@H]1C(=CC)[C@@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-BMIGLBTASA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000006886 spatial memory Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (12)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010136863.3A CN102204904B (zh) | 2010-03-31 | 2010-03-31 | 左旋奥拉西坦在制备预防或治疗认知功能障碍药物中的应用 |
CN201410451786.9A CN104173336B (zh) | 2010-03-31 | 2010-03-31 | 左旋奥拉西坦在制备预防或治疗认知功能障碍药物中的应用 |
PCT/CN2010/076707 WO2011120281A1 (zh) | 2010-03-31 | 2010-09-08 | 左旋奥拉西坦在制备预防或治疗认知功能障碍药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010136863.3A CN102204904B (zh) | 2010-03-31 | 2010-03-31 | 左旋奥拉西坦在制备预防或治疗认知功能障碍药物中的应用 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410451786.9A Division CN104173336B (zh) | 2010-03-31 | 2010-03-31 | 左旋奥拉西坦在制备预防或治疗认知功能障碍药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102204904A true CN102204904A (zh) | 2011-10-05 |
CN102204904B CN102204904B (zh) | 2014-10-01 |
Family
ID=44694149
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201010136863.3A Active CN102204904B (zh) | 2010-03-31 | 2010-03-31 | 左旋奥拉西坦在制备预防或治疗认知功能障碍药物中的应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN102204904B (zh) |
WO (1) | WO2011120281A1 (zh) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102512419A (zh) * | 2011-11-10 | 2012-06-27 | 成都苑东药业有限公司 | 一种药物组合物及其制备方法 |
CN102600130A (zh) * | 2012-03-26 | 2012-07-25 | 北京阜康仁生物制药科技有限公司 | 奥拉西坦及其光学异构体的新临床用途 |
CN102871959A (zh) * | 2012-05-31 | 2013-01-16 | 北京阜康仁生物制药科技有限公司 | 稳定的(s)-4-羟基-2-氧代-1-吡咯烷乙酰胺药物组合物 |
WO2013075459A1 (zh) * | 2011-11-23 | 2013-05-30 | 重庆润泽医药有限公司 | 左旋奥拉西坦、奥拉西坦在制备预防或治疗昏迷药物中的应用 |
CN103599083A (zh) * | 2013-12-06 | 2014-02-26 | 重庆东泽医药科技发展有限公司 | 左旋奥拉西坦缓释片及其制备方法 |
CN104739796A (zh) * | 2013-12-27 | 2015-07-01 | 重庆东泽医药科技发展有限公司 | 一种奥拉西坦片剂及其制备方法 |
CN106619530A (zh) * | 2015-10-27 | 2017-05-10 | 重庆润泽医药有限公司 | 一种左旋奥拉西坦颗粒及其制备方法 |
CN106955274A (zh) * | 2016-07-13 | 2017-07-18 | 重庆润泽医药有限公司 | 一种(s)‑4‑羟基‑2氧代‑1‑吡咯烷乙酰胺缓释胶囊及其制备方法 |
CN106955275A (zh) * | 2016-07-14 | 2017-07-18 | 重庆润泽医药有限公司 | 一种稳定性好的左旋奥拉西坦缓释胶囊及其制备方法 |
CN106511307B (zh) * | 2015-09-11 | 2018-10-23 | 重庆润泽医药有限公司 | 一种(s)-4-羟基-2氧代-1-吡咯烷乙酰胺缓释胶囊及其制备方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116919348B (zh) * | 2023-07-28 | 2024-04-16 | 河北医科大学第二医院 | 一种检测奥拉西坦药物治疗认知功能障碍效果的检测系统 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1390543A (zh) * | 2002-07-25 | 2003-01-15 | 湖南省岳阳市制药三厂 | 注射用奥拉西坦药品 |
CN101239938A (zh) * | 2008-03-10 | 2008-08-13 | 苏州凯达生物医药技术有限公司 | (s)-4-羟基吡咯烷酮及其衍生物的制备方法 |
CN101367757A (zh) * | 2008-10-13 | 2009-02-18 | 重庆润泽医疗器械有限公司 | 一种(s)-4-羟基-2-氧代-1-吡咯烷乙酰胺的制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9121289D0 (en) * | 1991-10-08 | 1991-11-20 | Isf Spa | Composition and use |
CN1555794A (zh) * | 2004-01-02 | 2004-12-22 | 肖广常 | 奥拉西坦分散片及其制备方法 |
-
2010
- 2010-03-31 CN CN201010136863.3A patent/CN102204904B/zh active Active
- 2010-09-08 WO PCT/CN2010/076707 patent/WO2011120281A1/zh active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1390543A (zh) * | 2002-07-25 | 2003-01-15 | 湖南省岳阳市制药三厂 | 注射用奥拉西坦药品 |
CN101239938A (zh) * | 2008-03-10 | 2008-08-13 | 苏州凯达生物医药技术有限公司 | (s)-4-羟基吡咯烷酮及其衍生物的制备方法 |
CN101367757A (zh) * | 2008-10-13 | 2009-02-18 | 重庆润泽医疗器械有限公司 | 一种(s)-4-羟基-2-氧代-1-吡咯烷乙酰胺的制备方法 |
Non-Patent Citations (3)
Title |
---|
尹浩等: "奥拉西坦改善高血压脑出血患者认知功能的对照研究", 《四川医学》 * |
巫光辉: "奥拉西坦治疗血管性认知功能障碍的疗效观察", 《中国实用神经疾病杂志》 * |
郁毅刚等: "奥拉西坦治疗中、重型脑损伤认知障碍临床研究", 《中华神经外科疾病研究杂志》 * |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102512419A (zh) * | 2011-11-10 | 2012-06-27 | 成都苑东药业有限公司 | 一种药物组合物及其制备方法 |
WO2013075459A1 (zh) * | 2011-11-23 | 2013-05-30 | 重庆润泽医药有限公司 | 左旋奥拉西坦、奥拉西坦在制备预防或治疗昏迷药物中的应用 |
CN102600130A (zh) * | 2012-03-26 | 2012-07-25 | 北京阜康仁生物制药科技有限公司 | 奥拉西坦及其光学异构体的新临床用途 |
CN102871959A (zh) * | 2012-05-31 | 2013-01-16 | 北京阜康仁生物制药科技有限公司 | 稳定的(s)-4-羟基-2-氧代-1-吡咯烷乙酰胺药物组合物 |
CN105125515B (zh) * | 2013-12-06 | 2018-07-13 | 重庆润泽医药有限公司 | 一种左旋奥拉西坦片剂及其制备方法 |
CN103599083B (zh) * | 2013-12-06 | 2015-10-21 | 温州智创科技有限公司 | 左旋奥拉西坦缓释片及其制备方法 |
CN105125515A (zh) * | 2013-12-06 | 2015-12-09 | 温州智创科技有限公司 | 一种左旋奥拉西坦片剂及其制备方法 |
CN103599083A (zh) * | 2013-12-06 | 2014-02-26 | 重庆东泽医药科技发展有限公司 | 左旋奥拉西坦缓释片及其制备方法 |
CN104739796A (zh) * | 2013-12-27 | 2015-07-01 | 重庆东泽医药科技发展有限公司 | 一种奥拉西坦片剂及其制备方法 |
CN104739796B (zh) * | 2013-12-27 | 2017-09-22 | 重庆润泽医药有限公司 | 一种奥拉西坦片剂及其制备方法 |
CN106511307B (zh) * | 2015-09-11 | 2018-10-23 | 重庆润泽医药有限公司 | 一种(s)-4-羟基-2氧代-1-吡咯烷乙酰胺缓释胶囊及其制备方法 |
CN106619530A (zh) * | 2015-10-27 | 2017-05-10 | 重庆润泽医药有限公司 | 一种左旋奥拉西坦颗粒及其制备方法 |
CN106955274A (zh) * | 2016-07-13 | 2017-07-18 | 重庆润泽医药有限公司 | 一种(s)‑4‑羟基‑2氧代‑1‑吡咯烷乙酰胺缓释胶囊及其制备方法 |
CN106955274B (zh) * | 2016-07-13 | 2018-10-23 | 重庆润泽医药有限公司 | 一种(s)-4-羟基-2氧代-1-吡咯烷乙酰胺缓释胶囊及其制备方法 |
CN106955275A (zh) * | 2016-07-14 | 2017-07-18 | 重庆润泽医药有限公司 | 一种稳定性好的左旋奥拉西坦缓释胶囊及其制备方法 |
CN106955275B (zh) * | 2016-07-14 | 2018-10-26 | 重庆润泽医药有限公司 | 一种稳定性好的左旋奥拉西坦缓释胶囊及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
WO2011120281A1 (zh) | 2011-10-06 |
CN102204904B (zh) | 2014-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102204904B (zh) | 左旋奥拉西坦在制备预防或治疗认知功能障碍药物中的应用 | |
CA3037089C (en) | Sublingual pharmaceutical composition of edaravone and (+)-2-borneol | |
ES2741146T3 (es) | Formulaciones farmacéuticas de nitrio y sus usos | |
CN104083363B (zh) | 奥拉西坦或左旋奥拉西坦在制药领域中的新应用 | |
CN105311622B (zh) | 一种治疗疼痛的联合用药物及其制剂、制备方法 | |
CN104173336A (zh) | 左旋奥拉西坦在制备预防或治疗认知功能障碍药物中的应用 | |
US10098856B2 (en) | Alternating sympathomimetic therapy for the treatment of respiratory ailments | |
CN103735545B (zh) | 左旋奥拉西坦、奥拉西坦在制备预防或治疗昏迷药物中的应用 | |
WO2008065339A1 (en) | Pharmaceutical composition of memantine | |
CN102552248B (zh) | 左旋奥拉西坦、奥拉西坦在制备预防或治疗昏迷药物中的应用 | |
CN103800337A (zh) | 一类治疗神经退行性疾病的化合物及其用途 | |
CN107281183B (zh) | 一种镇痛药物组合物 | |
CN109172600B (zh) | 一种药物组合物及其用途 | |
CN103751185A (zh) | 左旋奥拉西坦、奥拉西坦在制备预防或治疗昏迷药物中的应用 | |
EP0868915A1 (en) | An anti-spasmodic and antiinflammatory composition containing a NSAID, pentifenone and fenpiverinium | |
CA2202425A1 (en) | A novel anti-spasmodic and antiinflammatory composition and a process for the manufacture thereof | |
CN115998735A (zh) | 一种伏乌碱在制备镇痛药物中的应用 | |
Date | Electronic Signature Page | |
CN103804361A (zh) | 一类治疗神经退行性疾病的化合物及其用途 | |
CN103804291A (zh) | 一类治疗神经退行性疾病的化合物及其用途 | |
CN116211855A (zh) | 12-表-15-欧乌头碱及其衍生物在制备镇痛药物中的应用 | |
CN103800328A (zh) | 一类治疗神经退行性疾病的化合物及其用途 | |
CN112358477A (zh) | 一种用于治疗胆囊炎的药物及其制备方法 | |
CN106668865A (zh) | 用于治疗脑缺血的药物组合物、制剂及其应用 | |
CN101590083A (zh) | 一种与同类静脉制剂等效的银杏达莫口服制剂组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Rong Zuyuan Inventor after: Jin Lei Inventor after: Feng Hua Inventor after: Li Fei Inventor after: Li Bo Inventor after: You Chao Inventor after: Pang Qi Inventor after: Xu Nan Inventor after: Ye Lei Inventor before: Rong Zuyuan Inventor before: Ye Lei Inventor before: Chen Yuying Inventor before: Jin Lei Inventor before: Feng Hua Inventor before: Li Fei Inventor before: Wang Zhiqiang Inventor before: You Chao |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: RONG ZUYUAN YE LEI CHEN YUYING JIN LEI FENG HUA LI FEI WANG ZHIQIANG YOU CHAO TO: RONG ZUYUAN JIN LEI FENG HUA LI FEI LI BO YOU CHAO PANG QI XU NAN YE LEI |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: 400042 Chongqing city Yubei District Qinye Road No. 9 Applicant after: Chongqing Runze Pharmaceutical Co., Ltd. Address before: 401120 Chongqing city Yubei District Shuangfeng Bridge Street Airport Road No. 296 Building 1 yuan and 7 2- store Applicant before: Chongqing Runze Medical Instruments Ltd. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: CHONGQING RUNZE MEDICAL INSTRUMENTS LTD. TO: CHONGQING RUNZE PHARMACEUTICAL CO., LTD. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Ye Lei Inventor before: Rong Zuyuan Inventor before: Jin Lei Inventor before: Feng Hua Inventor before: Li Fei Inventor before: Li Bo Inventor before: You Chao Inventor before: Pang Qi Inventor before: Xu Nan Inventor before: Ye Lei |
|
ASS | Succession or assignment of patent right |
Owner name: CHONGQING DONGZE PHARMACEUTICAL TECHNOLOGY DEVELOP Free format text: FORMER OWNER: CHONGQING RUNZE PHARMACEUTICAL CO., LTD. Effective date: 20150910 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150910 Address after: Chongqing city Shapingba District Yubei Road No. 50 of No. 13-15-6A Patentee after: DONGZE PHARMACEUTICAL SCIENCE AND TECHNOLOGY CO., LTD. Address before: 400042 Chongqing city Yubei District Qinye Road No. 9 Patentee before: Chongqing Runze Pharmaceutical Co., Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20170825 Address after: Chongqing city Yubei District Qinye Road No. 9 Patentee after: Chongqing Runze Pharmaceutical Co., Ltd. Address before: Chongqing city Shapingba District Yubei Road No. 50 of No. 13-15-6A Patentee before: DONGZE PHARMACEUTICAL SCIENCE AND TECHNOLOGY CO., LTD. |
|
TR01 | Transfer of patent right |